Surgery Websites
Thoracic Oncology Program »  Meet the Team »  Medical Oncologists »  Matthew A. Gubens, M.D., M.S.
Matthew A. Gubens, M.D., M.S.

Matthew A. Gubens, M.D., M.S.

Associate Clinical Professor of Medicine
Division of Hematology/Oncology
Department of Medicine

Contact Information

(415) 885-3882  Appointments
(415) 353-7151  Clinic Fax
Matthew.Gubens@ucsf.edu
Open Popup
  • 1993-1997, Yale University, New Haven, CT, BA, Ethics, Politics and Economics
  • 1998-2000, Harvard School of Public Health and Management, MS, Health Policy and Management
  • 2000-2005, Stanford University School of Medicine, MD
  • 2005-2008, UCSF, San Francisco, CA, Resident, Internal Medicine
  • 2008-2011, Stanford University, Stanford, CA, Fellow, Medical Oncology
  • American Board of Internal Medicine, Internal Medicine
  • Department of Medicine, Division of Hematology Oncology
  • Thoracic Oncology Program
  • UCSF Helen Diller Family Comprehensive Cancer Center
  • Thymoma & Thymic Carcinoma

Matthew Gubens, M.D., M.S. is a thoracic oncologist who treats patients with lung cancer, mesothelioma and other thoracic malignancies, including thymoma and thymic carcinoma, which are rare tumors of the mediastinum. He is an Assistant Clinical Professor of Medicine at UCSF.

His research involves designing clinical trials to study new compounds and treatment strategies in lung cancer. He and his colleagues have a special interest in translational medicine, and are actively working to translate laboratory-based findings to the clinic, especially for patients with epidermal growth factor receptor (EGFR) mutations, who are often young non-smokers.

Dr. Gubens earned his medical degree at Stanford, completed an internal medicine residency at UCSF and then a medical oncology fellowship at Stanford. He also holds an MS degree in Health Policy and Management from Harvard School of Public Health. Gubens is a member of the American Society of Clinical Oncology, the International Association for the Study of Lung Cancer, the International Thymic Malignancy Interest Group and the American College of Physicians.

Data provided by UCSF Profiles, powered by CTSI
MOST RECENT PUBLICATIONS FROM A TOTAL OF 46
Data provided by UCSF Profiles, powered by CTSI
  1. Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D'Amico TA, Dilling TJ, Dowell J, Gettinger S, Gubens MA, Hegde A, Hennon M, Lackner RP, Lanuti M, Leal TA, Lin J, Loo BW, Lovly CM, Martins RG, Massarelli E, Morgensztern D, Ng T, Otterson GA, Patel SP, Riely GJ, Schild SE, Shapiro TA, Singh AP, Stevenson J, Tam A, Yanagawa J, Yang SC, Gregory KM, Hughes M. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021. J Natl Compr Canc Netw. 2021 03 02; 19(3):254-266. View in PubMed
  2. Awad MM, Gadgeel SM, Borghaei H, Patnaik A, Yang JC, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Altan M, Jalal SI, Panwalkar A, Gubens M, Sequist LV, Saraf S, Zhao B, Piperdi B, Langer CJ. Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC. J Thorac Oncol. 2021 Jan; 16(1):162-168. View in PubMed
  3. Wu SY, Lazar AA, Gubens MA, Blakely CM, Gottschalk AR, Jablons DM, Jahan TM, Wang VEH, Dunbar TL, Wong ML, Chan JW, Guthrie W, Belkora J, Yom SS. Evaluation of a National Comprehensive Cancer Network Guidelines-Based Decision Support Tool in Patients With Non-Small Cell Lung Cancer: A Nonrandomized Clinical Trial. JAMA Netw Open. 2020 09 01; 3(9):e209750. View in PubMed
  4. Maynard A, McCoach CE, Rotow JK, Harris L, Haderk F, Kerr DL, Yu EA, Schenk EL, Tan W, Zee A, Tan M, Gui P, Lea T, Wu W, Urisman A, Jones K, Sit R, Kolli PK, Seeley E, Gesthalter Y, Le DD, Yamauchi KA, Naeger DM, Bandyopadhyay S, Shah K, Cech L, Thomas NJ, Gupta A, Gonzalez M, Do H, Tan L, Bacaltos B, Gomez-Sjoberg R, Gubens M, Jahan T, Kratz JR, Jablons D, Neff N, Doebele RC, Weissman J, Blakely CM, Darmanis S, Bivona TG. Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing. Cell. 2020 Sep 03; 182(5):1232-1251.e22. View in PubMed
  5. Herbst RS, Garon EB, Kim DW, Cho BC, Perez-Gracia JL, Han JY, Arvis CD, Majem M, Forster MD, Monnet I, Novello S, Szalai Z, Gubens MA, Su WC, Ceresoli GL, Samkari A, Jensen EH, Lubiniecki GM, Baas P. Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1?Positive, Advanced Non?Small-Cell Lung Cancer in the KEYNOTE-010 Study. J Clin Oncol. 2020 05 10; 38(14):1580-1590. View in PubMed
  6. View All Publications

 

Site Directory
    X